Skip to main content
Article thumbnail
Location of Repository

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay

By Veronika Auner, Gernot Kriegshäuser, Dan Tong, Reinhard Horvat, Alexander Reinthaller, Alexander Mustea and Robert Zeillinger
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2671522
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2002). AJ: Diagnostic biochip array for fast and sensitive detection of K-ras mutations in stool. Clin Chem
    2. (2005). Biochip for K-ras mutation screening in ovarian cancer. Clin Chem
    3. (1993). Birrer MJ: p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res
    4. (2004). De Goeij AP, et al.: In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
    5. (1999). EM: Genetic alterations in ovarian borderline tumours and ovarian carcinomas.
    6. (2007). Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study. Anticancer Res
    7. (2005). et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
    8. (1999). Frank TS: Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol
    9. (2003). Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol
    10. (2008). Herzog TJ: The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer.
    11. (2004). Ie M: Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res
    12. (2008). Ie M: Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.
    13. (1991). K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
    14. (1997). K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer
    15. (2008). Kras mutations and benefit from cetuximab in advanced colorectal cancer.
    16. (2008). KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
    17. (2008). KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
    18. (2003). Lohrs U: K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy. Lab Invest
    19. (2004). McCluggage WG: A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.
    20. (2007). Nederlof P: EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retroand prospective observations in non-small-cell lung cancer. Ann Oncol
    21. (1989). ras oncogenes in human cancer: a review. Cancer Res
    22. (2003). Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol
    23. (2007). W u S , W o n g T W , H u a n g X , T a k i m o t o C H , G o d w i n A K , et al.: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
    24. (2002). Zeillinger R: Genetic alterations in endometrial hyperplasia and cancer. Cancer Lett

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.